Physician profile
Patrick S Coleman
NPI 1376687020
$2,847.02
in general payments reported to CMS, 2019-2025
27 companies · $22.58 in 2025
The $22.58 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $490 · 2021: $475 · 2022: $395 · 2023: $469 · 2024: $39.14 · 2025: $22.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $669.26 | 2020-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Viiv Healthcare Company | $431.63 | 2019-2023 | Apretude |
| Novo Nordisk INC | $377.97 | 2019-2023 | Wegovy |
| Gilead Sciences, INC. | $164.10 | 2019-2021 | |
| Pfizer INC. | $157.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $139.66 | 2019-2021 | |
| Lilly USA, LLC | $104.03 | 2019-2021 | |
| Abbvie INC. | $75.21 | 2023 | Vraylar |
| Astellas Pharma US INC | $71.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $69.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.09 | 2019-2023 | Synjardy, Jardiance |
| Janssen Biotech, INC. | $65.83 | 2019 | |
| Glaxosmithkline, LLC. | $58.71 | 2019 | |
| Amarin Pharma, INC. | $54.39 | 2019-2020 | |
| Amgen INC. | $47.91 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $47.78 | 2023-2024 | Aptima |
| Astrazeneca Pharmaceuticals LP | $43.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.45 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.58 | 2025 | Caplyta |
| Topcon Healthcare Solutions, INC. | $22.08 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.94 | 2023 | Jornay Pm |
| Allergan, INC. | $17.90 | 2020 | |
| Shire North American Group INC | $17.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.64 | 2020 | |
| Eisai INC. | $15.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2020 | |
| Aytu Biopharma, INC. | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.